-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Immunome, Lowers Price Target to $30

Benzinga·11/10/2026 13:00:56
Listen to the news
Piper Sandler analyst Biren Amin maintains Immunome (NASDAQ:IMNM) with a Overweight and lowers the price target from $33 to $30.